Frontmatter

Articles in the same Issue

1. Frontmatter
2. Editorial
3. Critical role of laboratory medicine in the global response to the COVID-19 pandemic
4. Reviews
5. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis
6. COVID-19: progression of disease and intravascular coagulation – present status and future perspectives
7. IFCC Recommendations
8. Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce evaluation of the latest evidence
9. Biosafety measures for preventing infection from COVID-19 in clinical laboratories: IFCC Taskforce Recommendations
10. Opinion Papers
11. The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks
12. Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19)
13. Laboratory diagnostics within a modular hospital at the time of Coronavirus disease 2019 (COVID-19) in Wuhan
14. Original Articles
15. Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics
16. Comparison of throat swabs and sputum specimens for viral nucleic acid detection in 52 cases of novel coronavirus (SARS-Cov-2)-infected pneumonia (COVID-19)
17. Routine blood tests as a potential diagnostic tool for COVID-19
18. Laboratory predictors of death from coronavirus disease 2019 (COVID-19) in the area of Valcamonica, Italy
19. The hemocyte counts as a potential biomarker for predicting disease progression in COVID-19: a retrospective study
20. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection
21. The value of urine biochemical parameters in the prediction of the severity of coronavirus disease 2019
22. Letters to the Editor
23. COVID-19 infections are also affected by human ACE1 D/I polymorphism
24. No significant correlation between ACE Ins/Del genetic polymorphism and COVID-19 infection
25. ACE Ins/Del genetic polymorphism and epidemiological findings in COVID-19
26. Laboratory abnormalities in patients with COVID-2019 infection
27. Laboratory abnormalities in children with novel coronavirus disease 2019
28. Clinical laboratory and SARS-CoV-2 infection: where do we stand?
29. Clinical chemistry tests for patients with COVID-19 – important caveats for interpretation
30. Antibody tests for COVID-19: drawing attention to the importance of analytical specificity
31. Erythrocyte sedimentation rate is associated with severe coronavirus disease 2019 (COVID-19): a pooled analysis
32. One disease, different features: COVID-19 laboratory and radiological findings in three Italian patients
33. Decreased “WBC*LYM” was observed in SARS-CoV-2-infected patients from a fever clinic in Wuhan
34. Assessment of immune response to SARS-CoV-2 with fully automated MAGLUMI 2019-nCoV IgG and IgM chemiluminescence immunoassays
35. Coinfection of SARS-CoV-2 and multiple respiratory pathogens in children
36. The friendly use of chloroquine in the COVID-19 disease: a warning for the G6PD-deficient males and for the unaware carriers of pathogenic alterations of the G6PD gene
37. Potential interference of hydroxychloroquine-glucuronide metabolite on therapeutic drug monitoring of hydroxychloroquine using a mass spectrometry detector